LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the following investor conferences:
- Goldman Sachs 37th Annual Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 8, 2016 at 1:20 p.m. PDT
- William Blair 2016 Growth Stock Conference in Chicago, IL on Tuesday, June 14, 2016 at 11:30 a.m. CDT.
Live audio webcasts for these events will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. Archives will be available for 90 days.
Glaukos (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.